Two different problems, two different solutions

If your first question is 'should I have ChondroFiller or PRP for my cartilage defect?', the honest answer is that the question itself contains a hidden assumption — that the two treatments are alternatives for the same problem. They are not.

A focal full-thickness chondral defect is a structural void: a discrete gap in the cartilage surface where tissue is missing. Diffuse cartilage wear or osteoarthritis-driven joint inflammation is a biological environment problem: the tissue remaining in the joint is breaking down or inflamed, but there is no single defined hole to fill.

ChondroFiller is an injectable collagen scaffold. Placed under ultrasound guidance as an outpatient injection, it physically occupies and stabilises that structural void, giving the body a framework for repair. PRP — platelet-rich plasma — is also delivered by outpatient injection, but it works differently: it releases growth factors that modify the joint's biological environment, reducing inflammation and supporting the cartilage that remains.

The choice between them depends on which clinical problem is actually present, assessed by a specialist with imaging. Procedure type is not what separates them — both are injection-based treatments. Mechanism is.

What ChondroFiller does inside a focal defect

The scaffold itself sets the process in motion. ChondroFiller (manufactured by Meidrix Biomedicals GmbH) is a CE-marked Class III medical device — a cell-free Type I collagen hydrogel supplied in a dual-chamber syringe. Under ultrasound guidance it is injected directly into the defect as an outpatient appointment; the gel sets in situ within roughly three to five minutes, conforming precisely to the defect geometry without requiring a biopsy, bone drilling, or fibrin glue.

The mechanism is acellular matrix-induced chondrogenesis. The collagen scaffold is chemotactic — it draws the patient's own progenitor cells from surrounding synovium and subchondral bone into the defect space. Those cells populate the three-dimensional framework and, over a maturation period of approximately 12–24 months, promote endogenous repair of the damaged cartilage surface.

Published cohort data across more than 19,000 cases report approximately +30 IKDC score improvement in knee defects, +33 Harris Hip Score improvement in hip applications, and MOCART MRI regeneration scores of 70–87. These are outcome anchors from observational series — individual results depend on defect characteristics, joint loading, and patient factors that a clinical assessment is needed to determine.

Patient selection is central to those figures. The evidence supports use for discrete focal defects ideally up to approximately 2–2.5 cm², at ICRS grades II–IV, in joints without advanced underlying osteoarthritis. A 2021 prospective hip cohort (Mazek, n=26) found 17 of 21 treated patients achieved good or excellent results at three to five years — but patients with pre-existing osteoarthritis at Tönnis grade 2–3 had poor outcomes, establishing advanced OA as a clear patient-selection boundary.

What PRP does — and what it cannot do

Growth factors are the operative principle. When concentrated platelet plasma is injected intra-articularly, platelets release signalling proteins — including TGF-β, PDGF, and IGF-1 — that dampen inflammation, stimulate chondrocyte metabolism, and support the extracellular matrix surrounding existing cartilage tissue. The effect is environmental: PRP creates more favourable biological conditions inside the joint.

What it does not provide is a three-dimensional structure. Without a physical framework occupying a focal defect, growth factor release alone cannot fill a structural tissue gap or give recruited cells a stable surface on which to organise repair tissue. For a discrete hole in the cartilage surface, biological modulation without structural support is unlikely to address the underlying problem.

PRP's strongest evidence base is in settings where no such void exists. Extensive RCT data support its use for symptom relief in early-to-moderate knee osteoarthritis, where the goal is managing diffuse degradation rather than restoring focal structure. It also has a defined adjunctive role alongside surgical repair: a 2014 RCT (Manunta, n=20) found that PRP added to microfracture achieved IKDC scores of 84.2 versus 81 for microfracture alone at 12 months, suggesting PRP may accelerate functional recovery within a structurally supported environment — though the difference was not statistically significant at that follow-up point.

MRI-confirmed cartilage regeneration from PRP alone remains inconsistent across studies. Part of that variability reflects genuine biological heterogeneity; part reflects preparation differences. Leukocyte-rich and leukocyte-poor formulations, differing platelet concentrations, and variable activation protocols all affect growth-factor profiles, making cross-study comparison unreliable without knowing what preparation was actually used.

Which patients suit each treatment

The distinction maps onto a single clinical question: is there a structural void that needs to be filled, or is the joint environment the primary problem?

For ChondroFiller, the patient picture is typically someone with a focal defect confirmed on MRI — ideally younger or more physically active — where the clinical goal is genuine tissue repair rather than symptom management alone. The maturation timeline favours patients with long-term joint-health priorities over those seeking rapid, temporary relief. Where osteoarthritis has become widespread or advanced, scaffold repair is less likely to succeed in isolation: the surrounding joint environment is too degraded to support reliable endogenous repair consistently, a boundary that hip cohort evidence has established clearly.

PRP suits a different clinical profile. If imaging shows diffuse cartilage thinning or generalised chondropathy without a discrete full-thickness void, the structural-repair argument does not apply. The therapeutic need is environmental rather than architectural, and PRP's growth-factor mechanism fits that need more directly. PRP is also appropriate for patients who have undergone a structural procedure — microfracture, for example — and need biological support to optimise the healing environment during recovery.

Some patients find both treatments relevant at different points on the same pathway. PRP might settle joint inflammation ahead of a focal scaffold repair, or provide biological maintenance after one; ChondroFiller addresses the structural deficit that growth-factor therapy alone cannot fill. These are complementary roles at different stages, not interchangeable choices at the same decision point.

Specialist assessment — including weight-bearing imaging and MRI — is what maps an individual's findings onto these criteria. The framework here is a guide to that clinical conversation, not a substitute for it.

The honest state of the evidence

Calibrating expectations means engaging with the evidence hierarchy rather than taking headline figures at face value. ChondroFiller's clinical data comes primarily from cohort and observational studies — real-world series that carry meaningful weight at scale, but that sit below randomised controlled trials in the formal evidence hierarchy. Higher-level trial evidence is maturing; outcome figures from published series should be read as indicative benchmarks rather than personal guarantees.

PRP is backed by a larger body of RCT evidence overall, but most of those trials address osteoarthritis populations rather than focal full-thickness defects specifically — a distinction that matters when a patient's own picture does not match the trial design.

The most significant gap is comparative. No head-to-head RCT has directly tested ChondroFiller against PRP for focal chondral defects. This is not a red flag particular to either treatment; it reflects a genuine methodological challenge in designing a meaningful trial between interventions that operate at different therapeutic levels — one occupying a structural void, the other modifying the joint environment. A valid comparative trial would need patients whose profiles satisfy both protocols simultaneously, a narrow population that has so far made such a study practically difficult to run.

At consultation, the productive questions are: what evidence underpins this recommendation for my specific defect, and how will my joint be assessed before a treatment decision is made? Those questions are answerable — the absence of a head-to-head trial is not grounds to defer either option, only to hold outcome expectations appropriately.

Finding a specialist for your cartilage defect

The practical next step is a consultation with a specialist who can review your imaging — weight-bearing X-rays and MRI — to confirm defect type, size, and OA stage before any injection decision is made. That assessment is what converts the framework above into an answer specific to your joint.

Specialists offering ChondroFiller injection or PRP for cartilage conditions work in outpatient MSK settings across the UK. Search MSK lists them by region and specialty; filtering by treatment offered is a straightforward way to identify a clinician whose practice covers the relevant pathway near you.

Three questions worth bringing to that appointment:

• Is my defect focal and full-thickness, or is the cartilage loss more diffuse?
• What does my imaging show about the underlying OA stage?
• Which treatment fits my defect size, joint, and activity goals — and why?